UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038635
Receipt number R000043897
Scientific Title Randomized comparative study of the appearance of fixation and lip skin troubles due to differences in the shape of the double lumen bronchial tube flange
Date of disclosure of the study information 2019/12/20
Last modified on 2021/11/29 12:51:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized comparative study of the appearance of fixation and lip skin troubles due to differences in the shape of the double lumen bronchial tube flange

Acronym

Randomized comparative study of the appearance of fixation and lip skin troubles due to differences in the shape of the double lumen bronchial tube flange

Scientific Title

Randomized comparative study of the appearance of fixation and lip skin troubles due to differences in the shape of the double lumen bronchial tube flange

Scientific Title:Acronym

Randomized comparative study of the appearance of fixation and lip skin troubles due to differences in the shape of the double lumen bronchial tube flange

Region

Japan


Condition

Condition

This is mainly intended for patients undergoing thoracic surgery requiring separate lung ventilation, such as lung cancer, pneumothorax, empyema, and mediastinal tumor.

Classification by specialty

Chest surgery Anesthesiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The shape of the flange (a device for fixing the bronchial tube body to the patient and adjusting the position) attached to the Daiken Medical Co., Ltd. coudec double lumen was changed and sold by the company. Since the tape fixing method has been changed with the flange shape change, the degree of bronchial tube displacement and countermeasures for lip skin problems due to flange fixing will be examined.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1) New incidence: In each group, the number of new patients is divided by the number of target patients and calculated as a percentage.
Before and after tracheal intubation, observe the teeth and lips and exclude any damage caused by intubation.
2) Site and extent of damage:
The parts are classified into the lips, mouth corners, upper, lower, left and right around the mouth, the cheeks are above and below the nostrils, and the oral cavity is classified into the upper and lower parts of the alveoli and the tongue
The hard palate is excluded because it does not touch the structure.
3) Degree of damage: classified into redness, epidermal detachment, laceration, ulcer and blister
Sensory abnormalities include numbness, pain, and numbness
The range is described in mm (vertical * horizontal), and the depth is not evaluated because a measurable laceration is not expected.
Allows multiple selection of applicable items

Key secondary outcomes

1)Degree of bronchial tube displacement: When confirming the position of the tube with a bronchoscope, measure the distance (mm)from the tracheal branch to the tube opening for right lung ventilation to measure the extraction distance of the bronchoscope.
2)Safety assessment,Adverse events
Frequency of tube trouble: The case where the bronchial tube is displaced and the lung on the operation side swells or is inserted deeper and the position of the bronchial tube needs to be corrected during the operation.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Existing flange group

Interventions/Control_2

New flange group

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Intended for patients who meet all of the following criteria:
1)Patients undergoing thoracic surgery requiring separate lung ventilation
2) Patients using Daiken Medical Co., Ltd.'s codec double lumen left (37Fr/35Fr) 1)
3) Patients who are over 20 years old when obtaining consent (regardless of gender)
4) Patients who have received sufficient explanation for participation in this study, and who have obtained written consent from the patient or his / her proxy
1) Daiken Medical Equipment Co., Ltd. codec double lumen is sold only for the left side.
The new flange is not yet compatible with sizes 32Fr and 39Fr.

Key exclusion criteria

Patients who violate any of the following will not be included in this study:
1) Patients judged to be inappropriate by the study director
[Rationale for setting]
1) In order to leave room for the research director to decide whether or not to participate in this study, taking into account the general factors other than those mentioned above, taking into account the safety of the subject.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Ryuji
Middle name
Last name Kajikawa

Organization

IZumi City General Hospital

Division name

Department manager of Anesthesiology

Zip code

594-0073

Address

4-5-1 Wake-cho Izumi Osaka Japan

TEL

0725411331

Email

ryuji.kajikawa@tokushukai.jp


Public contact

Name of contact person

1st name Ryuji
Middle name
Last name Kajikawa

Organization

IZumi City General Hospital

Division name

Department manager of Anesthesiology

Zip code

594-0073

Address

4-5-1 Wake-cho Izumi Osaka Japan

TEL

0725411331

Homepage URL


Email

ryuji.kajikawa@tokushukai.jp


Sponsor or person

Institute

IZumi City General Hospital

Institute

Department

Personal name



Funding Source

Organization

IZumi City General Hospital

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Mirai Iryo Research Center Inc

Address

1-8-7, Koji-machi, Chiyoda-ku, Tokyo 102-0083, Japan

Tel

03-3263-4801

Email

mirai-ec1@mirai-iryo.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 12 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Suspended

Date of protocol fixation

2019 Year 12 Month 04 Day

Date of IRB

2020 Year 01 Month 06 Day

Anticipated trial start date

2020 Year 01 Month 07 Day

Last follow-up date

2021 Year 12 Month 20 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 11 Month 19 Day

Last modified on

2021 Year 11 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043897


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name